Berit M. Pfitzner

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2K citations

Breast Oncology, Neoadjuvant Therapy, Medicine +9

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

Sibylle Loibl, Gϋnter von Minckwitz, Andreas Schneeweiß et al. · Journal of Clinical Oncology · 2014 · 247 citations · Full text

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Barbara Ingold Heppner, Michael Untch, Carsten Denkert et al. · Clinical Cancer Research · 2016 · 194 citations

Glutamate enrichment as new diagnostic opportunity in breast cancer

Jan Budczies, Berit M. Pfitzner, Balázs Győrffy et al. · International Journal of Cancer · 2014 · 131 citations · Full text

Breast Oncology, Chemoprevention Strategy, Biochemistry +13